Amitriptyline for migraine prophylaxis in adolescents

  • Yazid Dimyati Department of Child Health, University of Sumatera Utara Medical School/H. Adam Malik Hospital, Medan, North Sumatera
  • Astri Nurhayati Zulkifli Department of Child Health, University of Sumatera Utara Medical School/H. Adam Malik Hospital, Medan, North Sumatera
  • Pranoto Trilaksono Department of Child Health, University of Sumatera Utara Medical School/H. Adam Malik Hospital, Medan, North Sumatera
  • Johannes H. Saing Department of Child Health, University of Sumatera Utara Medical School/H. Adam Malik Hospital, Medan, North Sumatera
  • Bistok Saing Department of Child Health, University of Sumatera Utara Medical School/H. Adam Malik Hospital, Medan, North Sumatera
DOI: https://doi.org/10.14238/pi51.6.2011.338-44
Keywords: amitriptyline, prophylaxis, migraine, adolescents

Abstract

headaches in children and adolescents. Amitriptyline efficacy as a prophylactic treatment for migraine in adults has been widely studied, but there is limited data on its use in children and adolescents.

Objective To determine the efficacy of amitriptyline for prophylactic treatment of migraine in adolescents.

Methods We conducted a single-blind, randomized, clinical trial study in Medan, North Sumatra, from July to October 2009. All participants had migraines, according to the International Headache Society criteria. They were divided into two groups, receiving either 10 mg amitriptyline or a placebo daily for 3 months. Headache frequency (days per month), headache duration (hours) and information to assess functional disability according to the Pediatric Migraine Disability Assessment Scale (PedMIDAS) were recorded by subjects. Efficacy was measured before, during and after intervention.

Results A total of 98 patients, aged 12 – 19 years (mean age 14.7 years) enrolled and were divided into the amitriptyline and placebo groups. Compared with baseline, there were significant differences in headache frequency and PedMIDAS score in the amitriptyline group (P=0.001, 95% CI 2.02 to 2.94 and P=0.001, 95% CI 7.64 to 9.76, respectively), but not in the placebo group (P >0.05) after 3 months of treatment. We also found that amitriptyline significantly decreased headache frequency, duration, and functional disability compared to the placebo, after 3 months of treatment (P < 0.05).

Conclusion Amitriptyline was effective for prophylactic treatment of migraine in adolescents after 3 months of intervention.

References

1. Abu-Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol. 2010;52:1088-97.
2. Milde-Busch A, Heinrich S, Thomas S, Kühnlein A, Radon K, Straube A, et al. Quality of life in adolescents with headache: results from a population-based survey. Cephalalgia. 2010;30:713-21.
3. Hershey AD. Recent developments in pediatric headache. Curr Opin Neurol. 2010;23:249-53.
4. Hershey AD. Current approaches to the diagnosis and management of paediatric migraine. Lancet Neurol. 2010;9:190-204.
5. Lewis DW. Pediatric migraine. Neurol Clin. 2009;27:481-501.
6. Buchanan TM, Ramadan NM. Prophylactic pharmacotherapy for migraine headaches. Semin Neurol. 2006;26:188-98.
7. Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther. 2009;31:542-59.
8. Couch JR. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache. 2011;51:33-51.
9. Valguarnera F, Tanganelli P. The efficacy of withdrawal therapy in subjects with chronic daily headache and medication overuse following prophylaxis with topiramate and amitriptyline. Neurol Sci. 2010;31:S175-7.
10. Magalhães E, Menezes C, Cardeal M, Melo A. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg. 2010;112:463-6.
11. Yan L, Wang Q, Fu Q, Ye Q, Xiao H, Wan Q. Amitriptyline inhibits currents and decreases the mRNA expression of voltage-gated sodium channels in cultured rat cortical neurons. Brain Res. 2010;1336:1-9.
12. Lampl C, Huber G, Adl J, Luthringshausen G, Franz G, Marecek S, et al. Two different doses of amitriptyline ER in the prophylaxis of migraine: long-term results and predictive factors. Eur J Neurol. 2009;16:943-8.
13. Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg. 2008;110:979-84.
14. Gasbarri A, Arnone B, Pompili A, Cifariello A, Marini C, Tavares MC, et al. Emotional memory and migraine: effects of amitriptyline and sex related difference. Behav Brain Res. 2008;189:220-5.
15. Apostol G, Cady RK, Laforet GA, Robieson WZ, Olson E, Abi-Saab WM, et al. Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study. Headache. 2008;48:1012-25.
16. Lewis D, Paradiso E. A double-blind, dose comparison study of topiramate for prophylaxis of basilar-type migraine in children: a pilot study. Headache. 2007;47:1409-17.
17. Lakshmi CV, Singhi P, Malhi P, Ray M. Topiramate in the prophylaxis of pediatric migraine: a double-blind placebo-controlled trial. J Child Neurol. 2007;22:829-35.
18. Balottin U, Termine C. Recommendations for the management of migraine in paediatric patients. Expert Opin Pharmacother. 2007;8:731-44.
19. Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol. 2010;9:285-98.
20. Eiland LS, Jenkins LS, Durham SH. Pediatric migraine: pharmacologic agents for prophylaxis. Ann Pharmacother. 2007;41:1181-90.
21. Chong SC, Chan YH, Ong HT, Low PS, Tay SK. Headache diagnosis, disability and co-morbidities in a multi-ethnic, heterogeneous paediatric Asian population. Cephalalgia. 2010;30:953-61.
22. Fuh JL, Wang SJ, Lu SR, Liao YC, Chen SP, Yang CY. Headache disability among adolescents: a student population-based study. Headache. 2010;50:210-8.
23. Valentinis L, Valent F, Mucchiut M, Barbone F, Bergonzi P, Zanchin G. Migraine in adolescents: validation of a screening questionnaire. Headache. 2009;49:202-11.
24. Visudtibhan A, Boonsopa C, Thampratankul L, Nuntnarumit P, Okaschareon C, Khongkhatithum C, et al. Headache in junior high school students: types & characteristics in Thai children. J Med Assoc Thai. 2010;93:550-7.
25. Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia. 2010;30:1065-72.
26. Yadav RK, Kalita J, Misra UK. A study of triggers of migraine in India. Pain Med. 2010;11:44-7.
27. Anttila P, Metsahonkala L, Sillanpaa M. Long-term trends in the incidence of headache in Finnish schoolchildren. Pediatrics. 2006;117:1197-201.
Published
2011-12-31
How to Cite
1.
Dimyati Y, Zulkifli A, Trilaksono P, Saing J, Saing B. Amitriptyline for migraine prophylaxis in adolescents. PI [Internet]. 31Dec.2011 [cited 24Nov.2024];51(6):338-4. Available from: https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/861
Issue
Vol 51 No 6 (2011): November 2011
Section
Articles

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Received 2016-10-11
Accepted 2016-10-11
Published 2011-12-31